Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicotine patch claims are one quarter of 1997 OTC/supplement NAD reviews.

This article was originally published in The Tan Sheet

Executive Summary

NICOTINE REPLACEMENT PATCHES GENERATE A QUARTER OF NAD REVIEWS involving OTC drugs, dietary supplements and infant formulas in 1997. The National Advertising Division of the Council of Better Business Bureaus completed 16 OTC, supplement and formula cases during the year, of which four were smoking cessation patch products -- two for McNeil Consumer Product's Nicotrol and two for SmithKline Beecham's NicoDerm CQ. The number of OTC/supplement/formula cases is down 30% from 1996, when NAD completed 23 reviews, reflecting lower 1997 NAD totals in general due to limited resources and a smaller staff, as well as NAD's concentration on new product categories such as the telecommunications industry
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088126

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel